Abstract:Objectives: Cervical cancer is one of the most common female malignancies worldwide, a hypoxic microenvironment usually causes enhanced viability and glycolytic capacity of cervical cancer cells. The aim of this study was to investigate the association between chaperonin containing t-complex polypeptide 1 subunit 6A (CCT6A) and cell proliferation as well as hypoxic glycolysis. Design: Bioinformatics analysis was conducted to explore the association between cervical cancer and its partner protein under hypoxic conditions, namely CCT6A. Subsequently, the expression of CCT6A was silenced, and the effects of CCT6A silencing on cervical cancer cell proliferation, cell cycle, glycolysis-related proteins, and telomerase activity were examined. Materials, Setting, Methods: Bioinformatics analysis was performed to investigate the expression of CCT6A in cervical cancer under hypoxic conditions. The expression of CCT6A was silenced in cervical cancer cells, Hela and Siha, to study its effects on cell proliferation and hypoxic glycolysis. The localization of telomerase activity-related proteins, TCAB1 and TERT, was detected using immunofluorescence, and their interaction was assessed using immunoprecipitation. A cellular hypoxia model was established, and the products of the glycolysis reaction were detected. A nude mouse tumor model was constructed, and the changes in glycolysis-related proteins in tumor tissues were examined using western blot, while Ki67 expression in tumor tissues was evaluated by immunohistochemistry. Results: Telomerase activity was found to be enhanced in CCT6A-silenced cervical cancer cells, along with an increase in telomerase cajal body protein 1 (TCAB1) and telomerase reverse tranase (TERT) protein binding associated with telomerase activity. Additionally, the proportion of cells in the Gap 2/mitosis (G2/M) stage and the 5-ethynyl-2’-deoxyuridine (EdU) positivity rate were decreased in CCT6A-silenced cells, indicating a reduction in cell proliferation. The expression of cell cycle-related proteins, including Cyclin E, CCNA2 and cyclin-dependent kinase 2 (CDK2), was suppressed. Furthermore, under a hypoxic environment, silencing CCT6A led to a significant reduction in cell viability and downregulation of glycolysis-related proteins, such as lactate dehydrogenase A (LDHA) and hexokinase 2 (HK2). Mechanistically, silencing CCT6A may reduce telomerase activity by inhibiting the TCAB1/TERT interaction. Additionally, TERT was found to activate the promoter region of the HK2 gene, and inhibition of TERT activity reduced the transcriptional level of HK2. Limitations: The study primarily explored the involvement of CCT6A in cervical cancer, yet it did not account for the myriad of other elements potentially influencing cell proliferation and glycolysis. It's essential to recognize that cervical cancer's etiology is multifaceted, shaped by an array of genetic variations, environmental influences, and protein interactions. Conclusions: Silencing CCT6A could effectively attenuate the upregulation of cell proliferation and glycolytic function mediated by TCAB1/TERT in cervical cancer cells.

CCT6A facilitates lung adenocarcinoma progression and glycolysis via STAT1/HK2 axis

Suppression of CCT3 Inhibits Tumor Progression by Impairing ATP Production and Cytoplasmic Translation in Lung Adenocarcinoma.

CCT6A and CHCHD2 Are Coamplified with EGFR and Associated with the Unfavorable Clinical Outcomes of Lung Adenocarcinoma

CHAC1 blockade suppresses progression of lung adenocarcinoma by interfering with glucose metabolism via hijacking PKM2 nuclear translocation

HKDC1 promotes the tumorigenesis and glycolysis in lung adenocarcinoma via regulating AMPK/mTOR signaling pathway

Ccat1/Fabp5 Promotes Tumour Progression Through Mediating Fatty Acid Metabolism And Stabilizing Pi3k/Akt/Mtor Signalling In Lung Adenocarcinoma

SEC61 Translocon Gamma Subunit is Correlated with Glycolytic Activity, Epithelial Mesenchymal Transition and the Immune Suppressive Phenotype of Lung Adenocarcinoma

HSPE1 Enhances Aerobic Glycolysis to Promote Progression of Lung Adenocarcinoma

MCTS1 Promotes the Development of Lung Adenocarcinoma by Regulating E2F1 Expression

CCT6A regulates cervical cancer cell glycolysis and proliferation under hypoxic conditions via the TCAB1/TERT

Chaperonin-containing TCP-1 subunit genes are potential prognostic biomarkers and are correlated with Th2 cell infiltration in lung adenocarcinoma: An observational study

Exploring a new signature for lung adenocarcinoma: analyzing cuproptosis-related genes through Integrated single-cell and bulk RNA sequencing

Genomic analysis of hypoxia and mitophagy related genes with prognosis and characterization of the immune microenvironment in LUAD

UPP1 Promotes Lung Adenocarcinoma Progression through Epigenetic Regulation of Glycolysis

TFAP2A Upregulates SKA3 to Promote Glycolysis and Reduce the Sensitivity of Lung Adenocarcinoma Cells to Cisplatin

Long Non-Coding RNA GATA6-AS1 Inhibits Proliferation and Promotes Apoptosis of Lung Adenocarcinoma Through Sponging miR-331-3p and Regulating SOCS1/JAK2/STAT3 Pathway

LINC00665 promotes glycolysis in lung adenocarcinoma cells via the let-7c-5p/HMMR axis

C1QTNF6 As a Novel Biomarker Regulates Cellular Behaviors in A549 Cells and Exacerbates the Outcome of Lung Adenocarcinoma Patients

Targeting STT3A Produces an Anti-Tumor Effect in Lung Adenocarcinoma by Blocking the MAPK and PI3K/AKT Signaling Pathway.

Transketolase Serves As a Biomarker for Poor Prognosis in Human Lung Adenocarcinoma.

FSCN1 Induced PTPRF-dependent Tumor Microenvironment Inflammatory Reprogramming Promotes Lung Adenocarcinoma Progression Via Regulating Macrophagic Glycolysis